Cost-effective analysis of screening for biliary atresia with the stool color card

Journal of Pediatric Gastroenterology and Nutrition

Volumn 60, Issue 1, 2015, Pages 91-98

  Mogul, Douglas ^a   Zhou, Mo ^b   Intihar, Paul ^c   Schwarz, Kathleen ^a   Frick, Kevin ^d  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c JOHNS HOPKINS HOSPITAL   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

biliary atresia; cost effective analysis; screening; stool color

Indexed keywords

COTRIMOXAZOLE; FAT; LANSOPRAZOLE; MAGNESIUM OXIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; URSODEOXYCHOLIC ACID; VALGANCICLOVIR; VITAMIN;

ARTICLE; BILE DUCT ATRESIA; COST EFFECTIVENESS ANALYSIS; DIGESTIVE DIAGNOSTIC DEVICE; FECES COLOR; HEALTH CARE COST; HUMAN; LIFE EXTENSION; LIVER GRAFT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; SCREENING; SENSITIVITY ANALYSIS; SIMULATION; STOOL COLOR CARD; ADVERSE EFFECTS; BILIARY ATRESIA; CHEMISTRY; COHORT STUDIES; COLOR; EARLY DIAGNOSIS; ECONOMICS; FALSE POSITIVE REACTIONS; FEASIBILITY STUDIES; FECES; HEALTH CARE COSTS; HUMANS; INFANT, NEWBORN; LIVER TRANSPLANTATION; MARKOV CHAINS; METHODS; MORTALITY; NEONATAL SCREENING; PROGNOSIS; QUALITY-ADJUSTED LIFE YEARS; SENSITIVITY AND SPECIFICITY; UNITED STATES;

BILIARY ATRESIA; COHORT STUDIES; COLOR; EARLY DIAGNOSIS; FALSE POSITIVE REACTIONS; FEASIBILITY STUDIES; FECES; HEALTH CARE COSTS; HUMANS; INFANT, NEWBORN; LIVER TRANSPLANTATION; MARKOV CHAINS; NEONATAL SCREENING; PROGNOSIS; QUALITY-ADJUSTED LIFE YEARS; SENSITIVITY AND SPECIFICITY; UNITED STATES;

EID: 84920783813     PISSN: 02772116     EISSN: 15364801     Source Type: Journal    
DOI: 10.1097/MPG.0000000000000569     Document Type: Article

References (47)

1. Sokol RJ, Mack C, Narkewicz MR, et al. Pathogenesis and outcome of biliary atresia: current concepts. J Pediatr Gastroenterol Nutr 2003;37:4-21.
2. US Health Care Costs: Issue Modules, Background Brief. http://www. kaiseredu.org/issue-modules/US-health-care-costs/%20backgroundbrief. aspx#footnote1. Accessed February 14, 2013.
3. HHS Research Awards: Use of Recovery Act and Patient Protection and Affordable Care Act Funds for Comparative Effectiveness Research. http://www.gao.gov/products/GAO-11-712R. Accessed June 27, 2013.
4. Schreiber RA, Barker CC, Roberts EA, et al. Biliary atresia: the Canadian experience. J Pediatr 2007;151:659-65665.e1.
5. Tiao M-M, Tsai S-S, Kuo H-W, et al. Epidemiological features of biliary atresia in Taiwan, a national study 1996-2003. J Gastroenterol Hepatol 2008;23:62-6.
6. Hung P-Y, Chen C-C, Chen W-J, et al. Long-Term prognosis of patients with biliary atresia: a 25 year summary. J Pediatr Gastroenterol Nutr 2006;42:190-5.
7. Schwarz KB, Haber BH, Philip R, et al. Extra-hepatic anomalies in infants with biliary atresia: results of a large prospective North American multi-center study. Hepatology 2013;58:1724-31.
8. Chen S-M, Chang M-H, Du J-C, et al. Screening for biliary atresia by infant stool color card in Taiwan. Pediatrics 2006;117:1147-54.
9. Muraji T. Early detection of biliary atresia: past, present & future. Expert Rev Gastroenterol Hepatol 2012;6:583-9.
10. Wildhaber BE. Screening for biliary atresia: Swiss stool color card. Hepatology 2011;54:367-9.
11. Tseng J-J, Lai M-S, Lin M-C, et al. Stool color card screening for biliary atresia. Pediatrics 2011;128:e1209-15.
12. Hsiao C-H, Chang M-H, Chen H-L, et al. Universal screening for biliary atresia using an infant stool color card in Taiwan. Hepatology 2008;47:1233-40.
13. Lien T-H, Chang M-H, Wu J-F, et al. Effects of the infant stool color card screening program on 5-year outcome of biliary atresia in Taiwan. Hepatology 2011;53:202-8.
14. Yoon PW, Bresee JS, Olney RS, et al. Epidemiology of biliary atresia: a population-based study. Pediatrics 1997;99:376-82.
15. Wildhaber BE, Majno P, Mayr J, et al. Biliary atresia: Swiss national study, 1994-2004. J Pediatr Gastroenterol Nutr 2008;46:299-307.
16. Chardot C, Buet C, Serinet M-O, et al. Improving outcomes of biliary atresia: French national series 1986-2009. J Hepatol 2013;58:1209-17.
17. Davenport M, Ong E, Sharif K, et al. Biliary atresia in England and Wales: results of centralization and new benchmark. J Pediatr Surg 2011;46:1689-94.
18. McKiernan PJ, Baker AJ, Lloyd C, et al. British paediatric surveillance unit study of biliary atresia: outcome at 13 years. J Pediatr Gastroenterol Nutr 2009;48:78-81.
19. Oh SH, Kim KM, Kim DY, et al. Clinical experience of more than 200 cases of pediatric liver transplantation at a single center: improved patient survival. Transplant Proc 2012;44:484-6.
20. Ng VL, Alonso EM, Bucuvalas JC, et al. Health status of children alive 10 years after pediatric liver transplantation performed in the US and Canada: report of the studies of pediatric liver transplantation experience. J Pediatr 2012;160:820.e3-6.e3.
21. Ueda M, Oike F, Ogura Y, et al. Long-Term outcomes of 600 living donor liver transplants for pediatric patients at a single center. Liver Transpl 2006;12:1326-36.
22. Farmer DG, Venick RS, McDiarmid SV, et al. Predictors of outcomes after pediatric liver transplantation: an analysis of more than 800 cases performed at a single institution. J Am Coll Surg 2007;204:904-14.
23. Neto JS, Pugliese R, Fonseca EA, et al. Four hundred thirty consecutive pediatric living donor liver transplants: variables associated with posttransplant patient and graft survival. Liver Transpl 2012;18:577-84.
24. Fouquet V, Alves A, Branchereau S, et al. Long-Term outcome of pediatric liver transplantation for biliary atresia: a 10-year follow-up in a single center. Liver Transpl 2005;11:152-60.
25. Diem HVT, Evrard V, Vinh HT, et al. Pediatric liver transplantation for biliary atresia: results of primary grafts in 328 recipients. Transplantation 2003;75:1692-7.
26. Jain A, Mazariegos G, Pokharna R, et al. The absence of chronic rejection in pediatric primary liver transplant patients who are maintained on tacrolimus-based immunosuppression: a long-Term analysis. Transplantation 2003;75:1020-5.
27. Tannuri ACA, Gibelli NEM, Ricardi LRS, et al. Orthotopic liver transplantation in biliary atresia: a single-center experience. Transplant Proc 2011;43:181-3.
28. Ng V, Anand R, Martz K, et al. Liver retransplantation in children: a SPLIT database analysis of outcome and predictive factors for survival. Am J Transplant 2008;8:386-95.
29. De Vries W, de Langen ZJ, Groen H, et al. Biliary atresia in the Netherlands: outcome of patients diagnosed between 1987 and 2008. J Pediatr 2012;160:638.e2-44.e2.
30. Pringle B, Colpe LJ, Blumberg SJ, et al. Diagnostic history and treatment of school-Aged children with autism spectrum disorder and special health care needs. NCHS Data Brief 2012;97:1-8.
31. Wengrovitz AM, Brown MJ. Advisory Committee on Childhood Lead Poisoning, Division of Environmental and Emergency Health Services, National Center for Environmental Health, Centers for Disease Control and Prevention. Recommendations for blood lead screening of Medicaid-eligible children aged 1-5 years: an updated approach to targeting a group at high risk. MMWR Recomm Rep Morb Mortal Wkly Rep 2009;58 (RR-9):1-11.
32. Sharek PJ,Wayman K, Lin E, et al. Improved pain management in pediatric postoperative liver transplant patients using parental education and non-pharmacologic interventions. Pediatr Transplant 2006;10:172-7.
33. Bucuvalas JC, Ryckman FC, Atherton H, et al. Predictors of cost of liver transplantation in children: a single center study. J Pediatr 2001;139:66-74.
34. CodeManager: Standard j cpt Code/Relative Value Search. https:// ocm.ama-Assn.org/OCM/CPTRelativeValueSearch.do?submitbutton= accept. Accessed November 27, 2013.
35. GoldMR, ed. Cost-Effectiveness inHealth andMedicine. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996.
36. Moyer V, Freese DK, Whitington PF, et al. Guideline for the evaluation of cholestatic jaundice in infants: recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2004;39:115-28.
37. FASTSTATS-Births and Natality. http://www.cdc.gov/nchs/fastats/ births.htm. Accessed November 27, 2013.
38. Wilson J, Jungner G. Principles and Practice of Screening for Disease. Geneva: World Health Organization; 1968.
39. American Academy of Pediatrics Subcommittee on Hyperbilirubinemia. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics 2004;114:297-316.
40. Evers S, Goossens M, de Vet H, et al. Criteria list for assessment of methodological quality of economic evaluations: Consensus on Health Economic Criteria. Int J Technol Assess Health Care 2005;21:240-5.
41. Limbers CA, Neighbors K, Martz K, et al. Health-related quality of life in pediatric liver transplant recipients compared with other chronic disease groups. Pediatr Transplant 2011;15:245-53.
42. Lykavieris P, Chardot C, Sokhn M, et al. Outcome in adulthood of biliary atresia: a study of 63 patients who survived for over 20 years with their native liver. Hepatology 2005;41:366-71.
43. Shinkai M, Ohhama Y, Take H, et al. Long-Term outcome of children with biliary atresia who were not transplanted after the Kasai operation: 20-year experience at a children's hospital. J Pediatr Gastroenterol Nutr 2009;48:443-50.
44. De Vries W, Homan-Van der Veen J, Hulscher JBF, et al. Twenty-year transplant-free survival rate among patients with biliary atresia. Clin Gastroenterol Hepatol 2011;9:1086-91.
45. Alonso EM, Martz K, Wang D, et al. Factors predicting health-related quality of life in pediatric liver transplant recipients in the functional outcomes group. Pediatr Transplant 2013;17:605-11.
46. Harpavat S, Finegold MJ, Karpen SJ. Patients with biliary atresia have elevated direct/conjugated bilirubin levels shortly after birth. Pediatrics 2011;128:e1428-33.
47. Zhou K, Lin N, Xiao Y, et al. Elevated bile acids in newborns with biliary atresia (BA). PloS One 2012;7:e49270.